Biogen Files for U.S. Market Approval of AVONEX for Multiple Sclerosis Treatment

Strategic Insights -

Biogen, Inc. has made significant progress in its efforts to bring its recombinant interferon beta product, AVONEX, to market. The company has filed for U.S. Food and Drug Administration (FDA) approval, marking a crucial milestone in the development of this treatment for multiple sclerosis (MS). According to Jim Vincent, Biogen's Chairman and Chief Executive Officer, the company is "very encouraged" about the potential for AVONEX to become an important therapy for people with MS. Biogen plans to sell AVONEX in the U.S. and several major European markets, with commercial partners handling distribution in other key markets.

Key Takeaways:

  • Biogen has filed with the U.S. FDA for approval of its recombinant interferon beta product, AVONEX, for the treatment of multiple sclerosis (MS).
  • This marks the first time Biogen has filed for regulatory approval of a proprietary Biogen drug in the U.S.
  • AVONEX has also been filed with the European Medicines Evaluation Agency for European market approval.
  • Biogen will market AVONEX worldwide under the brand name AVONEX.
  • The company plans to focus on multiple sclerosis, inflammatory and respiratory diseases, and certain viruses and cancers as primary areas of product development.
  • Biogen's Chairman and Chief Executive Officer, Jim Vincent, expressed enthusiasm for the potential of AVONEX to become a key treatment for people with MS.
  • The company will work with commercial partners to distribute AVONEX in other key markets.

Statistics:

  • Biogen's revenues are generated from worldwide sales by licensees of products such as alpha interferon, hepatitis B vaccines, and diagnostic products.
  • The company has filed with the FDA for U.S. market approval and with the European Medicines Evaluation Agency for European market approval.
  • Biogen has announced that it has filed for both U.S. and European market approval of AVONEX earlier this month and today.
  • Biogen is a biopharmaceutical company headquartered in Cambridge, Massachusetts.

Sources:

  • "Biogen, Inc. Announces Filing of U.S. Market Application for AVONEX for Treatment of Multiple Sclerosis." Biogen, Inc. Press Release, May 22, 1995.
  • "AVONEX Product Overview." Biogen, Inc., [www.biogen.com](http://www.biogen.com).
  • "Contact Biogen." Biogen, Inc., [www.biogen.com](http://www.biogen.com).